Cytosolic Phospholipase A2 Determines Intercellular Heterogeneity of Stress Granules and Chemotherapy Response
| dc.contributor.author | Redding, Alexandra | |
| dc.contributor.author | Fonteneau, Guillaume | |
| dc.contributor.author | Heinrich, Stefan | |
| dc.contributor.author | Gaida, Matthias M. | |
| dc.contributor.author | Grabocka, Elda | |
| dc.date.accessioned | 2026-11-05T11:01:32Z | |
| dc.date.issued | 2025 | |
| dc.description.abstract | Cancer cell heterogeneity is a major therapeutic challenge. In this study, we identify that individual cells within cancer cell populations show significant heterogeneity in the levels of the stress-adaptive organelles, stress granules (SG), and demonstrate that SG heterogeneity is dictated by the cell cycle state. Specifically, SG formation is distinctively heightened in cells in the G2 phase because of the interplay between a nonapoptotic function of CASPASE-3 and calcium-dependent phospholipase A2 (cPLA2)-mediated production of the SG-promoting molecule, 15-deoxy-delta-prostaglandin-J2. We demonstrate that in the G1-S phase, CASPASE-3 cleaves and inactivates cPLA2, whereas in the G2 phase, CASPASE-3 activity is suppressed, resulting in enhanced cPLA2 activity and 15-deoxy-delta-prostaglandin-J2 upregulation. We show that cell cycle-dependent SG heterogeneity is a property of pancreatic ductal adenocarcinoma and targeting G2-SGs by inhibiting cPLA2 sensitizes pancreatic ductal adenocarcinoma to G2 arrest-inducing chemotherapeutics. Our findings highlight cell cycle-dependent SG formation as a fundamental property of SGs, a key aspect of cancer heterogeneity, and a target for cancer treatment.Significance: Because of their defective G1 checkpoint mechanisms, cancer cells often activate a G2 checkpoint, which leads to resistance to DNA-damaging chemotherapeutics. We identify an intercellular heterogeneity of SGs that is driven by the cell cycle, with SG formation being highest in the G2 phase. Targeting G2-specific SG formation sensitizes pancreatic tumors to G2 arrest-inducing chemotherapeutics. | |
| dc.description.issue | 7 | |
| dc.description.pages | 1437-1457 | |
| dc.description.sponsorship | This study was supported by an NIH/NCI R37CA230645 grant, a W. Kim Foster Pancreatic Cancer Pilot Grant, and the Thomas Jefferson University Department of Surgery to E. Grabocka, a NIH/NCI T32 grant in Cancer Biology (T32CA236736) to A. Redding, and grants of the German Research Foundation (Ga 1818/2-3, SFB1292 TPQ1 and TP22) to M.M. Gaida. The Thomas Jefferson University Flow Cytometry Core, Translational Research/Pathology Core, and Animal Core are shared facilities partially supported by the National Cancer Center Support Grant (P30 CA056036) to the Sidney Kimmel Cancer Center at Jefferson. | |
| dc.description.volume | 15 | |
| dc.identifier.doi | 10.1158/2159-8290.CD-24-1144 | |
| dc.identifier.issn | 2159-8274 | |
| dc.identifier.issn | 2159-8290 | |
| dc.identifier.uri | https://doi.org/10.1158/2159-8290.CD-24-1144 | |
| dc.identifier.uri | https://openaccess.acibadem.edu.tr/handle/11443/10751 | |
| dc.identifier.wos | WOS:001523203300006 | |
| dc.language.iso | en | |
| dc.publisher | AMER ASSOC CANCER RESEARCH | |
| dc.relation.funding | National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA) | |
| dc.relation.funding | NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)) | |
| dc.relation.funding | W. Kim Foster Pancreatic Cancer Pilot Grant | |
| dc.relation.funding | Thomas Jefferson University Department of Surgery | |
| dc.relation.funding | NIH/NCI T32 grant in Cancer Biology | |
| dc.relation.funding | German Research Foundation(German Research Foundation (DFG)) | |
| dc.relation.funding | National Cancer Center Support Grant | |
| dc.relation.funding | National Institutes of Health (NIH) [R37CA230645] | |
| dc.relation.funding | NIH/NCI | |
| dc.relation.funding | Thomas Jefferson University Department of Surgery [T32CA236736] | |
| dc.relation.funding | NIH/NCI T32 grant in Cancer Biology [Ga 1818/2-3, SFB1292 TPQ1, TP22] | |
| dc.relation.funding | German Research Foundation [P30 CA056036] | |
| dc.relation.hasversion | 10.1158/2159-8290.CD-24-1144 | |
| dc.relation.ispartof | CANCER DISCOVERY | |
| dc.subject | CELL-CYCLE | |
| dc.subject | LIPID MEDIATOR | |
| dc.subject | INHIBITION | |
| dc.subject | APOPTOSIS | |
| dc.subject | SWITCH | |
| dc.subject | TRANSLATION | |
| dc.subject | OXALIPLATIN | |
| dc.subject | PRINCIPLES | |
| dc.subject | 15D-PGJ2 | |
| dc.subject | A(2) | |
| dc.subject | Oncology | |
| dc.title | Cytosolic Phospholipase A2 Determines Intercellular Heterogeneity of Stress Granules and Chemotherapy Response | |
| dc.type | Article | |
| oaire.citation.edition | Science Citation Index Expanded (SCI-EXPANDED) | |
| oaire.citation.endPage | 1457 | |
| oaire.citation.issue | 7 | |
| oaire.citation.startPage | 1437 | |
| oaire.citation.volume | 15 | |
| person.identifier.orcid | 0000-0001-7196-8498 | |
| person.identifier.orcid | 0000-0002-7369-4360 | |
| person.identifier.orcid | 0000-0002-2834-1398 |
